Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alcohol and drug addiction are major public health problems, and existing treatments are only moderately effective. Although there has been interest for over half a century in the therapeutic use of classic hallucinogens to treat addictions, clinical research with these drugs was halted at an early stage in the early 1970s, leaving many fundamental questions unanswered. In the past two decades, clinical research on classic hallucinogens has resumed, although addiction treatment trials are only now beginning. The purpose of this paper is to provide a targeted review of the research most relevant to the therapeutic potential of hallucinogens, and to integrate this information with current thinking about addiction and recovery. On the basis of this information, we present a heuristic model which organizes a number of hypotheses that may be tested in future research. We conclude that existing evidence provides a convincing rationale for further research on the effects of classic hallucinogens in the treatment of addiction. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Cognitive consequences of forced compliance.
Festinger, L., & Carlsmith, J. M. (1959) · The Journal of Abnormal and Social Psychology · doi:10.1037/h0041593 · Cited by 2,945
Kotov, R., Gamez, W., Schmidt, F., & Watson, D. (2010) · Psychological Bulletin · doi:10.1037/a0020327 · Cited by 2,677 · cited 2×
“[115] In another recent meta-analysis, the authors characterized the substance use disorder profile as low in Conscientiousness and Agreeableness, with relatively weak effects on Neuroticism and Extraversion.”
BackgroundThe self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.11.1259 · Cited by 2,538 · cited 1×
“Although the self-medication hypothesis([105]) is a common explanation, the actual processes accounting for this comorbidity have been elusive.”
BackgroundWhat is Motivational Interviewing?
Rollnick, S., & Miller, W. R. (1995) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s135246580001643x · Cited by 1,737
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 8×
“Participants in the psilocybin group also reported significantly increased current personal well-being or life satisfaction two months after the session when compared to the active control group.([54])”
BackgroundResultInfluentialRelations between personality and coping: A meta-analysis.
Connor-Smith, J. K., & Flachsbart, C. (2007) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.93.6.1080 · Cited by 1,453
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 142
- Grinspoon L., 1997, Psychedelic Drugs Reconsidered
- Grof S., 2008, LSD Psychotherapy
- Leuner H., 1967, The Use of LSD in Psychotherapy and Alcoholism, 101
- Buckman J., 1967, The Use of LSD in Psychotherapy and Alcoholism, 83
- Hoffer A., 1967, The Use of LSD in Psychotherapy and Alcoholism, 343
- Sherwood J. N., 1962, The psychedelic experience–a new concept in psychotherapy, J. Neuropsychiatr., 4, 69
- Unger S. M., 1963, Mescaline, Lsd, Psilocybin, and Personality‐Change ‐ a Review, Psychiatry, 26, 111, 10.1080/00332747.1963.11023344 · DOI · Paper page
- 10.1001/archpsyc.1967.01730290009002 · DOI · Paper page
- 10.1037/h0088594 · DOI
- Savage C., 1966, The effects of psychedelic (LSD) therapy on values, personality, and behavior, Int. J. Neuropsychiatry, 2, 241
- 10.1080/00221309.1969.9710481 · DOI
- Abuzzahab F. S., 1971, A review of LSD treatment in alcoholism, Int. Pharmacopsychiat., 6, 223, 10.1159/000468273 · DOI · Paper page
- 10.3109/16066359609010756 · DOI · Paper page
- 10.1080/02791072.1998.10399714 · DOI · Paper page
- 10.1093/shm/hkl039 · DOI · Paper page
- Grof S., 1973, DPT as an adjunct in psychotherapy of alcoholics, Int. Pharmacopsychiat., 8, 104, 10.1159/000467979 · DOI · Paper page
- 10.1080/02791072.1977.10472060 · DOI
- Smart R. G., 1966, A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior, Q. J. Stud. Alcohol, 27, 469, 10.15288/qjsa.1966.27.469 · DOI · Paper page
- 10.1176/ajp.126.1.59 · DOI · Paper page
- 10.1097/00005053-197002000-00003 · DOI · Paper page
- Tomsovic M., 1970, Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation, Q. J. Stud. Alcohol, 31, 932, 10.15288/qjsa.1970.31.932 · DOI · Paper page
- M. W.Johnson R. R.Griffiths.Psilocybin in smoking cessation: A pilot study in118th Annual Meeting of the American Psychological Association San Diego CA 2010. · doi:10.1037/e609562010-001
- 10.1371/journal.pone.0009019 · DOI · Paper page
- 10.1016/j.bcp.2007.07.018 · DOI · Paper page
- Glennon R. A., 2009, Principles of Addiction Medicine, 215
- 10.1093/cercor/13.8.870 · DOI · Paper page
- 10.1016/j.pnpbp.2007.07.009 · DOI
- 10.1523/JNEUROSCI.1665-10.2010 · DOI · Paper page
- 10.1073/pnas.0708862105 · DOI · Paper page
- 10.1016/j.neulet.2011.01.046 · DOI · Paper page
- 10.1111/j.1471-4159.2008.05357.x · DOI · Paper page
- Vaidya V. A., 1997, 5‐HT2A receptor‐mediated regulation of brain‐derived neurotrophic factor mRNA in the hippocampus and the neocortex, J. Neurosci., 17, 2785, 10.1523/JNEUROSCI.17-08-02785.1997 · DOI · Paper page
- 10.1016/j.neubiorev.2009.11.009 · DOI · Paper page
- Buckholtz N. S., 1990, Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain, Neuropsychopharmacol., 3, 137
- 10.1097/00005053-196312000-00007 · DOI · Paper page
- Pahnke W. N., 1971, The experimental use of psychedelic (LSD) psychotherapy, Int. Z. Klin. Pharmakol. Ther. Toxikol., 4, 446
- Stace W. T., 1960, Mysticism and Philosophy
- Pahnke W. N., 1969, Psychedelic drugs and mystical experience, Int. Psychiatry Clin., 5, 149
- 10.2307/1384454 · DOI · Paper page
- 10.1371/journal.pone.0014074 · DOI
- Roberts T. B., 1995, Religion and Psychoactive Sacraments: A Bibliographic Guide
- Kunitz S. J., 1994, Drinking Careers: A Twenty‐Five Year Study of Three Navajo Populations
- Halpern J. H., 2008, Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament, Med. Sci. Monit., 14, SR15
- 10.1080/02791072.2009.10399905 · DOI · Paper page
- 10.1177/009164718301100406 · DOI · Paper page
- Pahnke W., 1963, Drugs and Mysticism: An Analysis of the Relationship between Psychedelic Drugs and the Mystical Consciousness
- 10.1016/j.jep.2005.04.022 · DOI · Paper page
- Stewart O., 1987, The Peyote Religion: A History
- Meyerhoff B., 1974, Peyote Hunt
- Lu L., 2009, Traditional Medicine in the Treatment of Drug Addiction, Am. J. Drug Alcohol Ab., 35, 11
- 10.1525/maq.2000.14.4.521 · DOI
- 10.1016/j.biopsych.2005.06.038 · DOI · Paper page
- 10.1002/jclp.20000 · DOI · Paper page
- Emrick C. D., 2004, American Psychiatric Publishing Textbook of Substance Abuse Treatment, 433
- 1981, Twelve Steps and Twelve Traditions
- Wilson B., 2000, My First Forty Years
- 10.1002/jclp.20004 · DOI · Paper page
- 10.1300/J020v21n04_02 · DOI
- 10.1300/J020v21n01_01 · DOI · Paper page
- 10.1111/j.1530-0277.2007.00499.x · DOI · Paper page
- 10.1037/0893-164X.10.2.90 · DOI · Paper page
- 10.1111/j.1530-0277.2010.01362.x · DOI · Paper page
- 10.1177/0269881108094300 · DOI · Paper page
- 10.1017/S1461145709000169 · DOI · Paper page
- Krystal J. H., 2007, Ketamine and the potential role for rapid‐acting antidepressant medications, Swiss Med. Wkly., 137, 215, 10.4414/smw.2007.11932 · DOI · Paper page
- 10.1007/s11920-007-0063-1 · DOI · Paper page
- 10.1016/j.biopsych.2008.09.029 · DOI · Paper page
- 10.1016/j.pbb.2007.10.003 · DOI
- 10.1111/j.1360-0443.2006.01423.x · DOI · Paper page
- 10.1080/02791072.1998.10399709 · DOI · Paper page
- Grant B. F., 2004, Prevalence and co‐occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions, Arch. Gen. Psychiat., 61, 10
- 10.1007/s00127-003-0597-4 · DOI · Paper page
- 10.1016/j.comppsych.2008.09.003 · DOI
- 10.1038/mp.2008.41 · DOI · Paper page
- 10.1016/S0740-5472(03)00118-1 · DOI
- 10.15288/jsad.2010.71.434 · DOI
- 10.1016/j.biopsych.2004.05.009 · DOI
- 10.1016/j.drugalcdep.2004.09.004 · DOI · Paper page
- 10.1001/jama.291.15.1887 · DOI · Paper page
- 10.1111/j.1530-0277.1996.tb05263.x · DOI
- LeMarquand D., 1994, Serotonin and alcohol intake, abuse, and dependence: findings of animal studies, Biol. Psychiatry, 36, 27
- 10.2190/DE.37.3.d · DOI · Paper page
- 10.1016/S0306-4603(98)00005-7 · DOI
- Dubey C., 2010, Five Factor correlates: A comparison of substance abusers and non‐substance abusers, J. Ind. Acad. Appl. Psychology, 36, 107
- 10.1186/1471-244X-8-22 · DOI · Paper page
- 10.1037/0022-3514.84.2.411 · doi:10.1037/0022-3514.84.2.411 · Paper page
- 10.1016/j.addbeh.2010.06.008 · DOI · Paper page
- 10.1006/jrpe.2001.2326 · DOI
- 10.1016/j.psychres.2004.07.013 · DOI
- 10.1300/J069v25n04_06 · DOI
- 10.1186/1471-244X-3-1 · DOI · Paper page
- 10.1093/alcalc/34.2.254 · DOI · Paper page
- 10.1016/j.pharmthera.2010.09.007 · DOI · Paper page
- 10.15288/jsad.2007.68.641 · DOI · Paper page
- 10.1016/j.drugalcdep.2009.03.009 · DOI · Paper page
- 10.1111/j.1465-3362.2011.00303.x · DOI · Paper page
- 10.1037/a0025204 · DOI
- Heinz A., 2008, Identifying the neural circuitry of alcohol craving and relapse vulnerability, Addit. Biol., 14, 12
- 10.1016/B978-0-12-385506-0.00010-7 · DOI
- 10.1192/bjp.bp.107.041228 · DOI
- 10.1111/j.1530-0277.2007.00390.x · DOI · Paper page
- 10.1016/S0278-5846(03)00081-2 · DOI · Paper page
- 10.1192/bjp.bp.110.084178 · DOI · Paper page
- 10.1016/j.bcp.2007.08.005 · DOI · Paper page
- Swift R. M., 1999, Medications and Alcohol Craving, Alcohol Res. Health, 23, 7
- 10.1016/j.neubiorev.2011.03.005 · DOI
- 10.1093/alcalc/34.2.244 · DOI · Paper page
- 10.1046/j.1360-0443.1995.9018712.x · DOI
- 10.1176/ajp.152.3.391 · DOI · Paper page
- 10.1111/j.1530-0277.1996.tb01686.x · DOI · Paper page
- 10.1111/j.1530-0277.2000.tb04648.x · doi:10.1111/j.1530-0277.2000.tb04648.x · Paper page
- 10.1001/archpsyc.1997.01830200024004 · DOI · Paper page
- 10.1097/00004850-199409000-00004 · DOI · Paper page
- 10.1038/clpt.1992.85 · DOI
- 10.1007/978-1-4899-1678-5_13 · DOI
- Naranjo C. A., 1991, Possible pharmacological probes for predicting and preventing relapse in treated alcoholics, Alcohol Alcohol. Suppl., 1, 523
- 10.1001/jama.284.8.963 · DOI · Paper page
- 10.1176/appi.ajp.2010.10050755 · DOI · Paper page
- 10.1007/s00213-002-1002-9 · DOI
- 10.1037/0033-295X.84.2.191 · DOI · Paper page
- Bandura A., 1994, Encyclopedia of Human Behavior, 14
- Bandura A., 2001, Self‐Efficacy: The Exercise of Control
- 10.1016/j.addbeh.2011.07.032 · DOI · Paper page
- 10.1080/00952990701653818 · DOI
- 10.15288/jsa.2006.67.562 · DOI
- DiClemente C. C., 1999, Motivation for Change and Alcoholism Treatment, Alcohol Res. Health, 23, 7
- 10.1111/1467-9280.00137 · DOI · Paper page
- 10.1037/a0017189 · DOI · Paper page
- Miller W. R., 2006, A consensus statement on defining change talk, MINT Bulletin, 13, 6
- 10.1111/j.1749-6632.1998.tb08242.x · DOI · Paper page
- 10.1177/0960327107087802 · DOI · Paper page
- 10.1111/j.1749-6632.2000.tb06677.x · DOI
- 10.1523/JNEUROSCI.17-22-08828.1997 · DOI · Paper page
- Frecska E., 2006, The adverse effects of hallucinogens from intramural perspective, Neuropsychopharmacol. Hung., 8, 189
- 10.1523/JNEUROSCI.3959-04.2005 · DOI · Paper page
- 10.1111/j.1369-1600.2010.00251.x · DOI · Paper page
- 10.1038/tp.2011.57 · DOI
- 10.1073/pnas.0711755105 · DOI · Paper page
- 10.1016/j.pharmthera.2008.12.001 · DOI · Paper page
- 10.1300/J020V09N01_09 · DOI · Paper page
- 10.1080/02791072.2007.10399860 · DOI · Paper page
- 10.1207/s15473333thp3404_7 · DOI · Paper page
Cited by
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
“Several plausible mechanisms of hallucinogen-facilitated treatments have been proposed (Bogenschutz and Pommy, 2012; Carhart-Harris et al., 2012, 2014; Ross, 2012; Vollenweider and Kometer, 2010).”
BackgroundPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 381
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Thomas, G., Lucas, P., Capler, N., Tupper, K., & Martin, G. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990003 · Cited by 330
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
“A number of persisting psychological changes have been proposed as possible mediators of effects of classic hallucinogens in the treatment of addiction (Bogenschutz and Pommy, 2012).”
Self-citationCessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066709 · Cited by 141
“Moreover, previous research has postulated that psychedelic-induced insight is a key factor in the acute psychological effects that ultimately lead to a change in addictive behaviour (Bogenschutz and Pommy, 2012).”
BackgroundWinkelman, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120011 · Cited by 126
“Bogenschutz and Pommy [18] propose that three wellestablished mechanisms that mediate recovery from addiction—reduction in craving, enhancement of selfefficacy, and increased motivation - can be affected through the therapeutic use of psychedelics through several of the mechanisms they activate.”
BackgroundInfluentialdos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
“…in the antidepressive, anxiolytic and antiaddictive effects of AYA and other hallucinogens (Baumeister et al., 2014; Bogenschutz and Johnson, 2016; Bogenschutz and Pommy, 2012; Dos Santos et al., 2016; Fortunato et al., 2009, 2010; Moreno et al., 2013; Ross, 2012; Vollenweider and Kometer, 2010).”
Argento, E., Capler, R., Thomas, G., Lucas, P., & Tupper, K. W. (2019) · Drug and Alcohol Review · doi:10.1111/dar.12985 · Cited by 102
Rothberg, R. L., Azhari, N., Haug, N. A., & Dakwar, E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120970879 · Cited by 97
Oliveira-Lima, A. J., Santos, R., Hollais, A. W., Gerardi-Junior, C. A., Baldaia, M. A., Wuo-Silva, R., Yokoyama, T. S., Costa, J. L., Malpezzi-Marinho, E. L. A., Ribeiro-Barbosa, P. C., et al. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.01.032 · Cited by 91
“After four decades banned fromhuman psychiatric research, hallucinogen research has resumed by using psilocybin, a serotonergic hallucinogen, to treat alcoholism and nicotine dependence [4].”
Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy
Loftis, J. M., & Huckans, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.011 · Cited by 47
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Pepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13
In vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates
Prabhakaran, J., DeLorenzo, C., Zanderigo, F., Knudsen, G. M., Gilling, N., Pratap, M., Jorgensen, M. J., Daunais, J., Kaplan, J. R., Parsey, R. V., et al. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30329 · Cited by 7
Metadata
- Authors
- Bogenschutz, M. P., & Pommy, J. M.
- Venue
- Drug Testing and Analysis
- Publisher
- Wiley
- Published
- 2012-07
- Volume
- 4
- Issue
- 7-8
- Pages
- 543-555
- ISSN
- 1942-7603 (ISSN-L)
- 1942-7611
- OpenAlex
- W1940682915
- Cited by
- 125
- References
- 42
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.